Your browser doesn't support javascript.
loading
The EndoC-ßH1 cell line is a valid model of human beta cells and applicable for screenings to identify novel drug target candidates.
Tsonkova, Violeta Georgieva; Sand, Fredrik Wolfhagen; Wolf, Xenia Asbæk; Grunnet, Lars Groth; Kirstine Ringgaard, Anna; Ingvorsen, Camilla; Winkel, Louise; Kalisz, Mark; Dalgaard, Kevin; Bruun, Christine; Fels, Johannes Josef; Helgstrand, Charlotte; Hastrup, Sven; Öberg, Fredrik Kryh; Vernet, Erik; Sandrini, Michael Paolo Bastner; Shaw, Allan Christian; Jessen, Carsten; Grønborg, Mads; Hald, Jacob; Willenbrock, Hanni; Madsen, Dennis; Wernersson, Rasmus; Hansson, Lena; Jensen, Jan Nygaard; Plesner, Annette; Alanentalo, Tomas; Petersen, Maja Borup Kjær; Grapin-Botton, Anne; Honoré, Christian; Ahnfelt-Rønne, Jonas; Hecksher-Sørensen, Jacob; Ravassard, Philippe; Madsen, Ole D; Rescan, Claude; Frogne, Thomas.
Afiliação
  • Tsonkova VG; Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark; University of Copenhagen, Department of Biomedical Sciences, Blegdamsvej 3B, DK-2200, Copenhagen, Denmark.
  • Sand FW; Novo Nordisk A/S, Diabetes Research, GLP-1 & T2D Pharmacology, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Wolf XA; Novo Nordisk A/S, Diabetes Research, GLP-1 & T2D Pharmacology, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Grunnet LG; Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Kirstine Ringgaard A; Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark; University of Copenhagen, Department of Biomedical Sciences, Blegdamsvej 3B, DK-2200, Copenhagen, Denmark.
  • Ingvorsen C; Novo Nordisk A/S, Diabetes Research, Histology & Imaging, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Winkel L; Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Kalisz M; Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Dalgaard K; Novo Nordisk A/S, Diabetes Research, GLP-1 & T2D Pharmacology, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Bruun C; Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Fels JJ; Novo Nordisk A/S, Discovery Biology & Technology, Research Bioanalysis, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Helgstrand C; Novo Nordisk A/S, Protein Engineering, Expression Technologies 1, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Hastrup S; Novo Nordisk A/S, Protein Engineering, Expression Technologies 1, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Öberg FK; Novo Nordisk A/S, Protein Engineering, Expression Technologies 1, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Vernet E; Novo Nordisk Research Center Seattle Inc., Protein Engineering, NNRC Seattle, Inc., 530 Fairview Avenue North, 98109, Seattle, WA, USA.
  • Sandrini MPB; Novo Nordisk A/S, Protein Engineering, Upstream Technologies, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Shaw AC; Novo Nordisk A/S, Protein Engineering, Characterisation & Modelling Technology, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Jessen C; Novo Nordisk A/S, Protein Engineering, Protein & Peptide Chemistry 2, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Grønborg M; Novo Nordisk A/S, Discovery Biology & Technology, Discovery ADME, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Hald J; Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Willenbrock H; Novo Nordisk A/S, Discovery Biology & Technology, Bioinformatics, Maaloev, Denmark.
  • Madsen D; Novo Nordisk A/S, Discovery Biology & Technology, Bioinformatics, Maaloev, Denmark.
  • Wernersson R; Intomics A/S, Lottenborgvej 26, DK-2800, Lyngby, Denmark.
  • Hansson L; Intomics A/S, Lottenborgvej 26, DK-2800, Lyngby, Denmark; Novo Nordisk Pharma Ltd., Research Centre Oxford, Bioinformatics, Novo Nordisk Ltd., 3 City Place Beehive Ring Road, Gatwick, RH6 0PA, West Sussex, United Kingdom.
  • Jensen JN; Novo Nordisk Pharma Ltd., Research Centre Oxford, Bioinformatics, Novo Nordisk Ltd., 3 City Place Beehive Ring Road, Gatwick, RH6 0PA, West Sussex, United Kingdom.
  • Plesner A; Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Alanentalo T; Novo Nordisk A/S, Diabetes Research, Histology & Imaging, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Petersen MBK; Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark; University of Copenhagen, DanStem, Blegdamsvej 3B, DK-2200, Copenhagen, Denmark.
  • Grapin-Botton A; University of Copenhagen, DanStem, Blegdamsvej 3B, DK-2200, Copenhagen, Denmark.
  • Honoré C; Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Ahnfelt-Rønne J; Novo Nordisk A/S, Diabetes Research, Histology & Imaging, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Hecksher-Sørensen J; Novo Nordisk A/S, Diabetes Research, Histology & Imaging, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Ravassard P; Institut du cerveau et de la moelle (ICM) - Hôpital Pitié-Salpêtrière, Boulevard de l'Hôpital, Sorbonne Universités, Inserm, CNRS, UPMC Univ, Paris 06, Paris, France.
  • Madsen OD; Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Rescan C; Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark.
  • Frogne T; Novo Nordisk A/S, Diabetes Research, Department of Islet & Stem Cell Biology, Novo Nordisk Park, 2760, Maaloev, Denmark. Electronic address: tfro@novonordisk.com.
Mol Metab ; 8: 144-157, 2018 02.
Article em En | MEDLINE | ID: mdl-29307512
OBJECTIVE: To characterize the EndoC-ßH1 cell line as a model for human beta cells and evaluate its beta cell functionality, focusing on insulin secretion, proliferation, apoptosis and ER stress, with the objective to assess its potential as a screening platform for identification of novel anti-diabetic drug candidates. METHODS: EndoC-ßH1 was transplanted into mice for validation of in vivo functionality. Insulin secretion was evaluated in cells cultured as monolayer and as pseudoislets, as well as in diabetic mice. Cytokine induced apoptosis, glucolipotoxicity, and ER stress responses were assessed. Beta cell relevant mRNA and protein expression were investigated by qPCR and antibody staining. Hundreds of proteins or peptides were tested for their effect on insulin secretion and proliferation. RESULTS: Transplantation of EndoC-ßH1 cells restored normoglycemia in streptozotocin induced diabetic mice. Both in vitro and in vivo, we observed a clear insulin response to glucose, and, in vitro, we found a significant increase in insulin secretion from EndoC-ßH1 pseudoislets compared to monolayer cultures for both glucose and incretins. Apoptosis and ER stress were inducible in the cells and caspase 3/7 activity was elevated in response to cytokines, but not affected by the saturated fatty acid palmitate. By screening of various proteins and peptides, we found Bombesin (BB) receptor agonists and Pituitary Adenylate Cyclase-Activating Polypeptides (PACAP) to significantly induce insulin secretion and the proteins SerpinA6, STC1, and APOH to significantly stimulate proliferation. ER stress was readily induced by Tunicamycin and resulted in a reduction of insulin mRNA. Somatostatin (SST) was found to be expressed by 1% of the cells and manipulation of the SST receptors was found to significantly affect insulin secretion. CONCLUSIONS: Overall, the EndoC-ßH1 cells strongly resemble human islet beta cells in terms of glucose and incretin stimulated insulin secretion capabilities. The cell line has an active cytokine induced caspase 3/7 apoptotic pathway and is responsive to ER stress initiation factors. The cells' ability to proliferate can be further increased by already known compounds as well as by novel peptides and proteins. Based on its robust performance during the functionality assessment assays, the EndoC-ßH1 cell line was successfully used as a screening platform for identification of novel anti-diabetic drug candidates.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Técnicas de Cultura de Células / Células Secretoras de Insulina / Hipoglicemiantes Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Técnicas de Cultura de Células / Células Secretoras de Insulina / Hipoglicemiantes Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article